Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Pulmonary arterial hypertension is a devastating disorder characterized by precapillary pulmonary hypertension not caused by respiratory disease, obstruction of the pulmonary arteries, or certain less ...

There is no cure for pulmonary arterial hypertension (PAH). However, treatment can lead to reduced symptoms and improved quality of life. PAH occurs when the pressure within the blood vessels linking ...

Pulmonary thromboendarterectomy is a surgery used to treat chronic thromboembolic pulmonary hypertension. It’s the treatment of choice for this condition. Chronic thromboembolic pulmonary hypertension ...

High blood pressure can indirectly cause shortness of breath by forcing the heart to work harder, which may lead to cardiovascular issues. Pulmonary hypertension, a specific type of high blood ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Background Current guidelines for the evaluation of chronic obstructive pulmonary disease (COPD) do not recommend screening for pulmonary hypertension (PH), despite the high prevalence and impact on ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.